Press Releases

    • DEC 20 2016

    ONC201 Glioblastoma Trial to Expand Based on Promising Initial Results

    Philadelphia, PA (December 20, 2016) – Oncoceutics announced that it will expand the ongoing study with ONC201 in recurrent glioblastoma at Massachusetts General Hospital (MGH) and Dana Farber Cancer Institute (DFCI) that is supported by a National Cancer Institute grant awarded to Oncoceutics.   Between January and April, MGH and DFCI enrolled 17 patients with

    • NOV 28 2016

    Oncoceutics Promotes Lee Schalop, MD, to Chief Operating Officer

    Philadelphia, PA (November 22, 2016) – Oncoceutics, Inc. announced today the promotion of Lee Schalop, MD, to Chief Operating Officer. Dr. Schalop, who is co-founder and previously served as the company’s Chief Business Officer, will continue to serve as a member of the leadership team of Oncoceutics and as a member of the Board of

    • NOV 15 2016

    Imipridone Activity Described in Multiple Abstracts at 2016 ASH Meeting

    Philadelphia, PA (November 15, 2016) – Oncoceutics, Inc. announced four abstracts describing the efficacy of its lead compound ONC201 and lead analog ONC212 were selected for the 2016 annual meeting of the American Society of Hematology (ASH).  The abstracts, detailing results from experiments designed and executed by the company as well as collaborators at the

    • SEP 27 2016

    Oncoceutics Receives Additional US Patent For ONC201 in Adenocarcinomas

    Philadelphia, PA (September 27, 2016) – Oncoceutics, Inc. announced that the United States Patent and Trademark Office (USPTO) has issued patent #9,452,165 for the use of ONC201 to treat cancers that are categorized as adenocarcinomas. Adenocarcinomas are cancers that form from epithelial cells with glandular origins or characteristics. They represent approximately 50% of all cancers,